ADDED
As of February 23, 2026, there were 82.4 million shares of the registrant s common stock, $0.10 par value, outstanding.
Department of Health and Human Services ACO accountable care organization HIPAA U.S.
Health Insurance Portability and Accountability Act of 1996, HITECH, and their implementing privacy, security, and breach notification regulations AI artificial intelligence HITECH U.S.
Health Information Technology for Economic and Clinical Health AWA U.S.
Animal Welfare Act IPA independent physician associations BLS Biopharma Laboratory Services IR Plan Incident Response Plan Board Board of Directors of Labcorp Holdings Inc.
ISO International Organization for Standardization CAD Canadian Dollar LCAH Laboratory Corporation of America Holdings CCPA California Consumer Privacy Act, as amended LDT laboratory-developed test CDCS Clinical Development and Commercialization Services MCO managed care organization CDS Clinical Decision Support MHRA U.K.
Medicines and Healthcare Products Regulatory Commission CDx Companion Diagnostic N/A not applicable cGMP Current Good Manufacturing Practice NAV net asset value CIRO Chief Information Risk Officer NIST National Institute of Standards and Technology CITO Chief Information and Technology Officer OCR U.S.
Office of Civil Rights CLFS Clinical Laboratory Fee Schedule OBBBA One Big Beautiful Bill Act CLIA U.S.
Centers for Medicare and Medicaid Services OIS Labcorp Office of Information Security CODM Chief Operating Decision Maker PAMA U.S.
Protecting Access to Medicare Act Common Stock common stock, par value $0.10 per share PFS Physician Fee Schedule COSO Committee of Sponsoring Organizations of the Treadway Commission PHI protected health information CRO contract research organization PSA prostate-specific antigen CSA U.S.
REMOVED
As of February 24, 2025, there were 83.7 million shares of the registrant s common stock, $0.10 par value, outstanding.
together with its subsidiaries (Labcorp or the Company), has made, and from time to time may otherwise make in its public filings, press releases and discussions by Company management, forward-looking statements concerning the Company s operations, performance and financial condition, as well as its strategic objectives.
changes in government and third-party payer regulations, reimbursement, or coverage policies or other future reforms in the United States (U.S.) healthcare system (or in the interpretation of current regulations), new insurance or payment systems, including state, regional or private insurance cooperatives (e.g., health insurance exchanges) affecting governmental and third-party coverage or reimbursement for commercial laboratory testing, including the impact of the U.S.
significant monetary damages, fines, penalties, assessments, refunds, repayments, damage to the Company s reputation, unanticipated compliance expenditures, and/or exclusion or debarment from or ineligibility to participate in government programs, among other adverse consequences, arising from enforcement of anti-fraud and abuse laws and other laws applicable to the Company in jurisdictions in which the Company conducts business; 3.
significant fines, penalties, costs, unanticipated compliance expenditures, and/or damage to the Company s reputation arising from the failure to comply with applicable privacy and security laws and regulations, including the U.S.
Health Insurance Portability and Accountability Act of 1996, the U.S.
Health Information Technology for Economic and Clinical Health Act, the European Union s General Data Protection Regulation, and similar laws and regulations in jurisdictions in which the Company conducts business; 4.
loss or suspension of a license or imposition of fines or penalties under, or future changes in, or interpretations of applicable licensing laws or regulations regarding the operation of clinical laboratories, the development and commercialization of laboratory-developed tests (LDTs), and the delivery of clinical laboratory test results, including, but not limited to, the U.S.
Clinical Laboratory Improvement Amendments of 1988, the European Union In Vitro Diagnostics Regulation, and similar laws and regulations in jurisdictions in which the Company conducts business; 5.
changes in and failure to comply with the applicable regulations of pharmaceutical and medical device regulators affecting the approval, availability of, and the selling and marketing of diagnostic tests including LDTs, drug development, or the conduct of drug development and medical device and diagnostic studies and trials, including regulations and policies of the U.S.